Pharmacological management of polycystic ovary syndrome

Carolyn Ee, Chau Thien Tay

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m2). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalAustralian Prescriber
Volume47
Issue number4
DOIs
Publication statusPublished - Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 Therapeutic Guidelines Ltd.

Keywords

  • anti-obesity drugs
  • antiandrogens
  • combined oral contraceptive pill
  • inositol
  • metformin
  • polycystic ovary syndrome
  • women’s health

Fingerprint

Dive into the research topics of 'Pharmacological management of polycystic ovary syndrome'. Together they form a unique fingerprint.

Cite this